02.06.2013 Views

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

130 CISPLATIN<br />

Mucosal<br />

Gingival pigmentation<br />

(1982): Dunagin WG, Semin Oncol 9, 14<br />

Mucositis<br />

(2006): Langer CJ+, Cancer Invest 24(2), 164 (with paclitaxel)<br />

Oral lesions (5%)<br />

Oral ulceration (10%)<br />

(2006): Ochi T+, Nippon Hinyokika Gakkai Zasshi 97(6), 777<br />

(with gemcitabine)<br />

(2005): Daponte A+, Anticancer Res 25(2B), 1441 (14%) (with<br />

temozolomide)<br />

(2003): Belpomme D+, Gynecol Oncol 91(1), 32 (with<br />

gemcitabine)<br />

(2001): Sakai H+, Cancer Chemother Pharmacol 48(6), 499 (with<br />

paclitaxel)<br />

(1996): Planting AS+, Eur J Cancer 32A, 2026<br />

(1992): Zaun H+, Hautarzt (German) 43, 215<br />

(1989): Umeki S+, Chemotherapy 35, 54<br />

Nails<br />

Nails – Beau’s lines (transverse nail b<strong>and</strong>s)<br />

(1994): Ben-Dyan D+, Acta Haematol 91, 89<br />

Nails – hypomelanosis<br />

(1983): James WD+, Arch Dermatol 119, 334<br />

Other<br />

Anaphylactoid reactions/Anaphylaxis (

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!